Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic to Close $15M Private Placement of Common Stock

NEW YORK, Sept. 23 (GenomeWeb News) - Transgenomic has received commitments from institutional investors for a $15 million private placement of common stock, the company said today.


The investors, led by Lehman Brothers, have committed to purchase 15 million shares of Transgenomic's common stock priced at $1.01 per share. In addition, they will receive warrants to purchase another six million shares. The transaction, which is subject to shareholder approval and other conditions, is expected to close by the end of October.


Transgenomic said it will use net proceeds from the offering to repay its debt of approximately $9 million with Laurus Masters and for "general working capital needs."


"This private placement strengthens our balance sheet and better positions us to pursue the opportunities we've identified within our BioSystems business," said Transgenomic CEO Collion D'Silva in a company statement.


Earlier this week, Transgenomic escaped delisting on the Nasdaq exchange after its share price closed at or above $1 for 10 consecutive business days.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.